The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Blinatumomab-Global Market Insights and Sales Trends 2025
Synopsis
Blinatumomab (trade name Blincyto) is a biopharmaceutical drug used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia.
The global Blinatumomab market size is expected to reach US$ 1292 million by 2029, growing at a CAGR of 6.4% from 2023 to 2029. The market is mainly driven by the significant applications of Blinatumomab in various end use industries. The expanding demands from the Hospital and Pharmacy, are propelling Blinatumomab market. Prefilled, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Non-prefilled segment is estimated at % CAGR for the next seven-year period.
Blinatumomab received regulatory approvals in various countries for the treatment of ALL, further expanding its market reach and increasing demand.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Blinatumomab, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Blinatumomab market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Blinatumomab market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Blinatumomab sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Blinatumomab covered in this report include Amgen. etc.
The global Blinatumomab market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Amgen
Global Blinatumomab market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Blinatumomab market, Segment by Type:
Prefilled
Non-prefilled
Global Blinatumomab market, by Application
Hospital
Pharmacy
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Blinatumomab manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Blinatumomab in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Blinatumomab (trade name Blincyto) is a biopharmaceutical drug used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia.
The global Blinatumomab market size is expected to reach US$ 1292 million by 2029, growing at a CAGR of 6.4% from 2023 to 2029. The market is mainly driven by the significant applications of Blinatumomab in various end use industries. The expanding demands from the Hospital and Pharmacy, are propelling Blinatumomab market. Prefilled, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Non-prefilled segment is estimated at % CAGR for the next seven-year period.
Blinatumomab received regulatory approvals in various countries for the treatment of ALL, further expanding its market reach and increasing demand.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Blinatumomab, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Blinatumomab market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Blinatumomab market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Blinatumomab sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Blinatumomab covered in this report include Amgen. etc.
The global Blinatumomab market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Amgen
Global Blinatumomab market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Blinatumomab market, Segment by Type:
Prefilled
Non-prefilled
Global Blinatumomab market, by Application
Hospital
Pharmacy
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Blinatumomab manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Blinatumomab in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Blinatumomab Market Overview
1.1 Blinatumomab Product Overview
1.2 Blinatumomab Market Segment by Type
1.2.1 Prefilled
1.2.2 Non-prefilled
1.3 Global Blinatumomab Market Size by Type
1.3.1 Global Blinatumomab Market Size Overview by Type (2018-2029)
1.3.2 Global Blinatumomab Historic Market Size Review by Type (2018-2023)
1.3.3 Global Blinatumomab Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Blinatumomab Sales Breakdown by Type (2018-2023)
1.4.2 Europe Blinatumomab Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Blinatumomab Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Blinatumomab Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Blinatumomab Sales Breakdown by Type (2018-2023)
2 Global Blinatumomab Market Competition by Company
2.1 Global Top Players by Blinatumomab Sales (2018-2023)
2.2 Global Top Players by Blinatumomab Revenue (2018-2023)
2.3 Global Top Players by Blinatumomab Price (2018-2023)
2.4 Global Top Manufacturers Blinatumomab Manufacturing Base Distribution, Sales Area, Product Type
2.5 Blinatumomab Market Competitive Situation and Trends
2.5.1 Blinatumomab Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Blinatumomab Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Blinatumomab as of 2022)
2.7 Date of Key Manufacturers Enter into Blinatumomab Market
2.8 Key Manufacturers Blinatumomab Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Blinatumomab Status and Outlook by Region
3.1 Global Blinatumomab Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Blinatumomab Historic Market Size by Region
3.2.1 Global Blinatumomab Sales in Volume by Region (2018-2023)
3.2.2 Global Blinatumomab Sales in Value by Region (2018-2023)
3.2.3 Global Blinatumomab Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Blinatumomab Forecasted Market Size by Region
3.3.1 Global Blinatumomab Sales in Volume by Region (2024-2029)
3.3.2 Global Blinatumomab Sales in Value by Region (2024-2029)
3.3.3 Global Blinatumomab Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Blinatumomab by Application
4.1 Blinatumomab Market Segment by Application
4.1.1 Hospital
4.1.2 Pharmacy
4.2 Global Blinatumomab Market Size by Application
4.2.1 Global Blinatumomab Market Size Overview by Application (2018-2029)
4.2.2 Global Blinatumomab Historic Market Size Review by Application (2018-2023)
4.2.3 Global Blinatumomab Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Blinatumomab Sales Breakdown by Application (2018-2023)
4.3.2 Europe Blinatumomab Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Blinatumomab Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Blinatumomab Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Blinatumomab Sales Breakdown by Application (2018-2023)
5 North America Blinatumomab by Country
5.1 North America Blinatumomab Historic Market Size by Country
5.1.1 North America Blinatumomab Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Blinatumomab Sales in Volume by Country (2018-2023)
5.1.3 North America Blinatumomab Sales in Value by Country (2018-2023)
5.2 North America Blinatumomab Forecasted Market Size by Country
5.2.1 North America Blinatumomab Sales in Volume by Country (2024-2029)
5.2.2 North America Blinatumomab Sales in Value by Country (2024-2029)
6 Europe Blinatumomab by Country
6.1 Europe Blinatumomab Historic Market Size by Country
6.1.1 Europe Blinatumomab Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Blinatumomab Sales in Volume by Country (2018-2023)
6.1.3 Europe Blinatumomab Sales in Value by Country (2018-2023)
6.2 Europe Blinatumomab Forecasted Market Size by Country
6.2.1 Europe Blinatumomab Sales in Volume by Country (2024-2029)
6.2.2 Europe Blinatumomab Sales in Value by Country (2024-2029)
7 Asia-Pacific Blinatumomab by Region
7.1 Asia-Pacific Blinatumomab Historic Market Size by Region
7.1.1 Asia-Pacific Blinatumomab Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Blinatumomab Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Blinatumomab Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Blinatumomab Forecasted Market Size by Region
7.2.1 Asia-Pacific Blinatumomab Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Blinatumomab Sales in Value by Region (2024-2029)
8 Latin America Blinatumomab by Country
8.1 Latin America Blinatumomab Historic Market Size by Country
8.1.1 Latin America Blinatumomab Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Blinatumomab Sales in Volume by Country (2018-2023)
8.1.3 Latin America Blinatumomab Sales in Value by Country (2018-2023)
8.2 Latin America Blinatumomab Forecasted Market Size by Country
8.2.1 Latin America Blinatumomab Sales in Volume by Country (2024-2029)
8.2.2 Latin America Blinatumomab Sales in Value by Country (2024-2029)
9 Middle East and Africa Blinatumomab by Country
9.1 Middle East and Africa Blinatumomab Historic Market Size by Country
9.1.1 Middle East and Africa Blinatumomab Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Blinatumomab Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Blinatumomab Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Blinatumomab Forecasted Market Size by Country
9.2.1 Middle East and Africa Blinatumomab Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Blinatumomab Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Amgen
10.1.1 Amgen Company Information
10.1.2 Amgen Introduction and Business Overview
10.1.3 Amgen Blinatumomab Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Amgen Blinatumomab Products Offered
10.1.5 Amgen Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Blinatumomab Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Blinatumomab Industrial Chain Analysis
11.4 Blinatumomab Market Dynamics
11.4.1 Blinatumomab Industry Trends
11.4.2 Blinatumomab Market Drivers
11.4.3 Blinatumomab Market Challenges
11.4.4 Blinatumomab Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Blinatumomab Distributors
12.3 Blinatumomab Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
